Skip to main content

CORRECTION article

Front. Pharmacol., 17 August 2023
Sec. Inflammation Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1236892

Corrigendum: Dauricine attenuates vascular endothelial inflammation through inhibiting NF-κB pathway

This article is a correction to:

  1. Dauricine Attenuates Vascular Endothelial Inflammation Through Inhibiting NF-κB Pathway

    1. Read original article
Ji Hu,&#x;Ji Hu1,2†Ru Chen,&#x;Ru Chen1,2†Jie An,,Jie An1,2,3Yilong Wang,,Yilong Wang1,2,4Minglu Liang,Minglu Liang1,2Kai Huang,,, Kai Huang1,2,5,6*
  • 1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 3Department of Cardiology, Handan First Hospital, Handan, China
  • 4Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
  • 5Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China
  • 6Hubei Clinical Research Center of Metabolic and Cardiovascular Disease, Huazhong University of Science and Technology, Wuhan, China

A Corrigendum on
Dauricine attenuates vascular endothelial inflammation through inhibiting NF-κB pathway

by Hu J, Chen R, An J, Wang Y, Liang M and Huang K (2021). Front. Pharmacol. 12:758962. doi: 10.3389/fphar.2021.758962

In the published article, there was an error regarding the Affiliation(s) for “Kai Huang.” In addition to having Affiliation(s) 1 and 2, “[5] Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China; [6] Hubei Clinical Research Center of Metabolic and Cardiovascular Disease, Huazhong University of Science and Technology, Wuhan, China” should also be included.

In the published article, there was an error in Figure 4C, as published. Images of the dauricine-treated (40 um + IL-1β) group in Figure 4C were jumbled with the dauricine-treated (20 um + IL-1β) group. The corrected (Figure 4C) and its caption “(C) Nuclear translocation of p65, as indicated by the immunofluorescence in HUVECs treated with IL-1β and dauricine (scale bar: 200 μm). DAPI was used for nuclear staining (blue). P65 (green) was stained with the Alexa Fluor 488 secondary antibody” appear as follows:

FIGURE 4
www.frontiersin.org

FIGURE 4. (C) Nuclear translocation of p65 as indicated by the immunofluorescence in HUVECs treated with IL-1β and dauricine (scale bar :200 μm). DAPI was used for nucleus staining (blue). P65 (green) was stained with a secondary antibody of Alexa Fluor 488.

Figure 4 (C) Nuclear translocation of p65 as indicated by the immunofluorescence in HUVECs treated with IL-1β and dauricine (scale bar :200 μm). DAPI was used for nucleus staining (blue). P65 (green) was stained with a secondary antibody of Alexa Fluor 488.

In the published article, there was an error in the Funding statement. The funding information was missing in the initial version. The correct Funding statement appears as follows:

“This study was supported by the National Natural Science Foundation of China (Nos: 81830014 and 91949201).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: dauricine, endothelial dysfunction, NF-κB pathway, acute lung injury, inflammation

Citation: Hu J, Chen R, An J, Wang Y, Liang M and Huang K (2023) Corrigendum: Dauricine attenuates vascular endothelial inflammation through inhibiting NF-κB pathway. Front. Pharmacol. 14:1236892. doi: 10.3389/fphar.2023.1236892

Received: 08 June 2023; Accepted: 15 June 2023;
Published: 17 August 2023.

Edited and reviewed by:

Yun Zhang, Shandong University, China

Copyright © 2023 Hu, Chen, An, Wang, Liang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kai Huang, huangkai_hust@126.com

†These authors contributed equally to this work and shared first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.